IL6 and immunoglobulin G4-related sclerosing disease: Our results indicate the use of fibroblasts might be a novel therapeutic target in IgG4-RD, which is consistent with the phenomenon that IL-6-producing fibroblasts exist in the submandibular glands of patients with IgG4-RD (64).